LABORATORY CORE

本计划项目的实验室核心的使命是提供一致和可靠的“状态”， 用于测量来自多发性骨髓瘤患者的血清和血浆样品中的细胞因子的“ART”测定 在假设驱动的临床试验中进行研究，以评估症状、疾病 （癌症）和癌症治疗。在一个地点协调和进行细胞因子测定， 一个实验室，在一个有经验的主任的指导下，将消除可变性， 分析结果的不一致性，并提供可在项目间进行比较的统一结果。 实验室核心与服务有关的具体目标是： 1.处理、存档和储存所有四个项目研究对象的所有标本; 2.使用Luminex Multiplex流式细胞微珠阵列（Multiplex）测量血清/血浆细胞因子水平 测定或酶免疫吸附测定; 3.通过测定健康供体的样本，建立待研究的每种细胞因子的正常范围; 4.为所有项目负责人、统计人员、护理和实验室提供科学和技术指导 确保工作的临床和生物学相关性以及对 数据。 在多发性骨髓瘤中，NF-κ B是组成性活性的，IL-6和血管生成因子的血浆水平升高， VEGF和bFGF与患者的高肿瘤负荷相关。实验室核心还 除了服务使命之外，还提出了一个由假设驱动的具体目标。我们将评估 血管生成细胞因子与接受化疗的多发性骨髓瘤患者临床反应的关系 诱导疗法我们假设对沙利度胺诱导治疗有反应的患者或 硼替佐米（详见项目i和项目4）将降低血管生成细胞因子bFGF的水平 和VEGF。

The mission of the Laboratory Core of this Program Project is to provide consistent and reliable "state-ofthe- art" assays to measure cytokines in serum and plasma samples from of patients with multiple myeloma being investigated in hypothesis-driven clinical trials to assess the relationship between symptoms, disease (cancer), and therapy for cancer. Having the cytokine assays coordinated and performed at one location, by a single laboratory and under the direction of an experienced director, will eliminate variability and inconsistency in assay findings and provide uniform results that can be compared across projects. The service-related Specific Aims of the Laboratory Core are to: 1. Process, archive, and store all specimens from the study subjects of all four projects; 2. Measure serum/plasma cytokine levels by using Luminex Multiplex Cytometric Bead Array (Multiplex) assays or enzyme immunosorbent assays; 3. Establish normal ranges for each cytokine to be studied by assaying samples from healthy donors; 4. Provide scientific and technical guidance to all project leaders, statisticians, and nursing and laboratory personnel to ensure the clinical and biological relevance of the work and appropriate interpretation of the data. In multiple myeloma, NF-KB is constitutively active and the elevated plasma level of IL-6 and angiogenic factors, VEGF and bFGF are correlated with high tumor burden of patients. The Laboratory Core also proposes a hj'pothesis-driven specific aim in addition to its service mission. We will evaluate angiogenic cytokines in relation to the clinical response of patients with multiple myeloma receiving induction therapy. We hypothesize that patients responding to induction therapy with thalidomide or bortezomib (detailed in Projects i and 4) would have a reduction in the level of angiogenic cytokines bFGF and VEGF.